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Summary 
Blood cells originate from hematopoietic stem cells that are located at different sites during ontogeny. 
Production of human stem calls  and their progeny in culture is expected to have important 
implications for experimental therapeutic strategies involving gene transfer and transplantation. 
Here we report striking differences between primitive hematopoietic cells purified from adult 
bone marrow, umbilical cord blood, and fetal liver in cytokine-supplemented, serum-free cultures. 
In  such cultures both  the fraction of responding cells  and  their ability to  produce CD34 + 
progenitor cells decreased markedly with the age of the cell donor. These results document extensive, 
ontogeny-related functional differences between primitive hematopoietic cells. 
T 
he cells that circulate in the blood are derived from hema- 
topoietic precursors that in the normal adult are located 
in the bone marrow (1). During mammalian ontogeny he- 
matopoietic precursor cells are first found in the yolk sac and 
then in the fetal liver (2).  Human umbilical cord blood is 
a rich source of hematopoietic precursor cells (3), which most 
likely represent a developmental stage intermediate between 
fetal liver and adult bone marrow. The proliferation of he- 
matopoietic cells is dependent on the presence of hematopoi- 
etic cytokines (4).  The recognition of the gene product of 
the Steel locus of the mouse as a potent synergistic growth 
factor for multipotent hematopoietic cells (5) has resulted in 
a number of studies aimed at the cultivation of primitive he- 
matopoietic cells in vitro (6-12). In all these studies impres- 
sive proliferative effects of Steel factor on (purified) hemato- 
poietic cells were observed, especially in combination with 
factors such as IL-1, IL-3, IL-6, and IL-11. The effects of Steel 
factor on the production of the most primitive hematopoi- 
etic cells have been less dramatic, suggesting that other growth 
factors or culture conditions that will allow "stir-renewal" 
of stem cells await to be discovered (13,  14). An alternative 
explanation is that the most primitive hematopoietic cells in 
adult bone marrow are part of a large pool of quiescent (pre- 
viously generated and long-lived) cells that is either main- 
tained in size or slowly depleted throughout the life span 
of an individual. Such a notion is supported by a large body 
of experimental data in the mouse (reviewed in reference 15) 
that, however, has to be reconciled with data in support of 
extensive proliferation of individual stem cells in vivo (16, 
17)  and in vitro (18). 
In recent studies we found that primitive human hemato- 
poietic ceils expressing CD34  (19) that were purified from 
adult bone marrow could sustain long-term in vitro hemato- 
poiesis, apparently without decreasing the size of the precursor 
cell population (20). Although limited production of CD34 + 
cells was partially responsible for maintaining the number 
of CD34 + cells in these cultures (21), these results suggested 
that the actual production of more primitive hematopoietic 
cells in humans could be restricted to early stages of develop- 
ment (e.g., fetal life).  To further study this possibility, we 
compared  the  in  vitro  production  of  CD34 +  colony- 
forming cells  from CD34 +  CD45RA l~ CD71 l~ stem cell 
"candidates"  (SCC) 1 that  were purified  from  adult  bone 
marrow, umbilical cord blood,  and fetal liver. 
Materials and Methods 
Bone marrow cells were retrieved from vertebral bodies ofcada- 
veric organ donors (20). Cord blood samples were obtained from 
damped umbilical cords at the time of birth of normal full-term 
pregnancies. Fetal liver cells  were obtained from elective, therapeutic 
abortions in the 10-16th wk of gestation. The use of human mate- 
rial in this study was approved  by local Institutional Review Boards 
as well as the Ethical Screening Committee of the University of 
British Columbia. All cells were previously frozen, separated using 
Ficoll-Hypaque, and processed for flow cytometry cell sorting as 
described previously (20, 21). 
Results and Discussion 
CD34 + CD45RA l~ CD71 l~ cells purified from various tis- 
sues were cultured in serum-free liquid cultures (20, 21) sup- 
plemented with IL-3 (20 ng/ml), IL-6 (10 ng/ml), Steel factor 
1 Abbreviation used in this paper: SCC, stem cell candidates. 
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increases in the total number of cells over a period of 7-12 d 
were observed that were repeated over a 5-wk culture period 
when CD34 + cells were sorted from expanded cultures and 
used to reinitiate (sub)cultures (Fig.  1). In agreement with 
previous studies (20, 21), the total number of CD34 + cells 
in cultures initiated with purified bone marrow cells remained 
more  or  less  constant.  In  contrast,  the  total  number  of 
CD34 + cells in cultures initiated with purified cord blood 
and fetal liver progenitors increased 31-250-fold and 490- 
3,200-fold, respectively, over the same culture period (results 
from three separate experiments). CD34 + cells that were re- 
covered from the cultures had a cloning efficiency  in methyl- 
cellulose medium that ranged from 14 to 46%, and the produc- 
tion of colony-forming cells corresponded to the production 
of CD34 + cells (Table 1). Interestingly, a clear shift towards 
the production of myeloid colony-forming ceils was observed 
with time, similar to that described by others (11, 22). These 
results indicate that the culture conditions used do not sup- 
port true self-renewal of fetal-derived stem cell "candidates" 
or, alternatively, that the latter were increasingly diluted by 
CD34 § cells with a more limited proliferative potential. 
The large and striking differences in culture between stem 
cell "candidates" purified from adult bone marrow, fetal liver, 
and cord blood are further illustrated in Fig. 2. In this repre- 
sentative experiment purified candidate stem cells were la- 
beled with the fluorescent tracking dye PKH26 (23) and ana- 
lyzed for CD34 expression and PKH26 fluorescence before 
and after 7 d of culture. Note that most CD34 § cells from 
bone marrow remained brightly labeled with PKH26 (indi- 
cating no or  single-cell divisions),  whereas most  CD34 § 
cells from cord blood and especially those from fetal liver 
had decreased PKH26 fluorescence (indicative of multiple di- 
visions) after 7  d  of culture.  Importantly, loss  of PKH26 
fluorescence of adult bone marrow ceils coincided with loss 
of CD34  expression,  whereas  large  numbers  of CD34 + 
PKH26-  cells were recovered from cultures initiated with 
fetal liver or umbilical cord blood cells. These results indi- 
cate that the differences between stem cell "candidates" purified 
from different sources were not restricted to the fraction of 
responding ceils, but included qualitative differences in the 
ability to generate CD34 §  daughter cells as well. 
Taken together, these observations indicate large functional 
differences between phenotypically similar hematopoietic cell 
populations derived from blood-forming tissues at different 
stages in ontogeny. Differences in the developmental poten- 
tial between purified fetal and adult hematopoietic cells were 
previously described for murine cells with respect to thymic 
maturation potential (24).  An increased replating potential 
of human CD34 + cells from umbilical cord blood compared 
with CD34 + cells from bone marrow was reported in a re- 
cent study (22).  Our findings are in agreement with those 
previous studies and suggest that the proliferation and differen- 
tiation potential of primitive hematopoietic cells may change 
extensively during ontogeny. In this respect, it will be of in- 
terest to determine if the common precursor for the hemato- 
poietic microenvironment and hematopoietic stem cells that 
was recently isolated from fetal bone marrow (25) can also 
be found in adult tissue. In view of the ontogeny-related differ- 
ences in the functional properties of purified primitive he- 
matopoietic cells reported here, a search for the genes that 
are differentially expressed in such cells is indicated (26, 27). 
A  possible  link between the limited proliferative potential 
of adult hematopoietic cells and the length of their telomeres 
(28)  also warrants further study. 
From a practical point of view it appears of interest to pursue 
numerical  expansion  of both  cord  blood  and  fetal  liver 
CD34 + progenitor cells for potential clinical use, as has been 
suggested for cord blood cells by others (29, 30). The number 
of nucleated (Ficolled) cells that can be obtained from a fetal 
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Figure  1.  Ontogeny-related  differences in 
production of CD34 + cells in culture. CD34 + 
CD45RA l~ CD71 l~ cells were purified from 
bone marrow (20),  umbilical cord blood, and 
fetal liver, and cultured in serum-free culture 
medium supplemented with IL-6,  IL-3,  Steel 
factor (mast cell growth factor [MGF]),  and 
Epo  as  described  previously  (20).  Cultures 
(1  ml  each)  were  initiated  with  104  sorted 
cells.  At the indicated time interval the total 
number  of nucleated  ceils ([~)  and  CD34 + 
cells (ll) present in the cultures was calculated 
from the cell counts and the percentage of viable 
CD34 + calls measured by flow cytometry. All 
CD34 + cells from bone marrow cultures and 
fractions of the CD34 + cells from cord blood 
and fetal liver cultures were sorted and used 
for continuation of the cultures and measure- 
ments  of  clonogenic  cells  (Table  1).  Only 
CD34 +  cells  with  the  same  (high)  CD34 
fluorescence as the cells sorted from primary tissues were sorted for replating. Plotted data points of a representative experiment (n  =  3) were corrected 
for loss of cells during labeling and sorting as well as the fraction of sorted cells that was replated. In this particular experiment, CD34 + cells repre- 
sented 14.1,  1.7,  and 10.7%  of all viable low-density cells from, respectively, organ donor bone marrow,  umbilical cord blood, and fetal liver (13-15 
wk of gestation).  The corresponding  fraction of CD34 + CD45RA l~ CD71 l~ cells among CD34 + cells  from these tissues was,  respectively 30,  35, 
and  10%. 
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Cloning 
Cell type  Day  ef~ciency  CFU-c  BFU-e  CFU-mix 
% 
BM SCC  0  13  494  494  312 
7  26  2,602  575  203 
16  15  2,967  103  379 
25  14  2,604  0  196 
CB SCC  0  25  1,050  550  900 
7  30  20,250  1,580  675 
16  22  69,960  0  0 
25  17  187,000  0  0 
FL SCC  0  46  1,472  1,288  1,840 
7  33  187,968  6,336  16,896 
16  25  878,600  38,200  38,200 
25  17  3,128,000  0  0 
SCC from bone marrow (BM), umbilical cord blood (CB),  and fetal liver (FL) were purified and CD34 + cells recovered from the liquid cultures 
as described in the legend to Fig. 1. Sorted CD34 § cells were plated in methylcellulose medium for measurements of clonogenic cells (20). Colonies 
were scored 14-21 d later and the results of a representative experiment are shown. The absolute number of myeloid- (CFU-c; including CFU-G, 
CFU-M, and CFU-GM), erythroid-  (burst forming unit-erythroid, BFU-e), and mixed myeloid-erythroid-  (CFU-mix) colony-forming  cells present 
at each time point was calculated from the fraction  of CD34 + cells plated and the calculated number of CD34+  cells present in the cultures  (see 
also legend to Fig. 1). Note the differences in clonogenic cell production between SCC from BM, CB, and FL and the shift towards  production 
of myeloid colony-forming cells upon prolonged culture. 
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Figure  2.  Ontogeny-related 
differences in response to a mixture 
of growth factors by highly purified 
hematopoietic cells. Fetal liver, cord 
blood, and adult bone marrow SCC 
with a CD34 + CD45RAIo CD71 Io 
phenotype were purified by FACS  | 
labeled with the membrane label 
PKH26 (21), and cultured in serum- 
free  medium supplemented  with 
lb6, IL- 3, MGF, and Epo. PKH26 
is a bright fluorescent dye that is 
stably incorporated  into the lipid 
bilayer  of  cell  membranes  and 
diluted among daughter cells upon 
division of the parental cells (21). 
In this representative experiment (n 
=  4), PKH26 was incorporated to 
different degrees in the three target 
cell populations resulting in differ- 
ences in PKH26 fluorescence  at day 
0 (top). PKH26  fluorescence was 
measured again at day 7 (bottom) and 
plotted against CD34 fluorescence. Note that the majority of adult bone marrow CD34 § cells maintained their PKH26 fluorescence, indicating little 
turnover during the 7 d of culture and a weak response to the growth factor mixture. In contrast,  practically all CD34 + cells from umbilical cord 
and fetal liver showed decreased levels of PKH26 fluorescence at day 7, indicating an active proliferative response that included production of CD34 + 
cells. Note that fetal liver CD34 § cells had a decreased PKH26 fluorescence compared with cord blood CD34 + cells, indicating a higher proliferative 
rate of the fetal cells. The numbers in the boxed areas represent the number of cells used to initiate the experiment (top) or the number of cells with 
the indicated phenotype that were recovered at day 7.  This number was calculated from total cell counts and phenotypic  analysis. 
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which  1-4%  are  CD34 +  CD45RA  l~ CD71 l~ (106 SSC/ 
liver). For cord blood, minimal estimates (29) of these figures 
are 50-200  x  106 cells total, of which 0.5-1% are CD34 + 
CD45RA  l~ CD71  l~ (also  'x,106 SCC/cord blood  sample). 
Upon culture for 25 d with the combination of growth factors 
used in this study, purified SCC from fetal liver and cord 
blood would be expected to yield, respectively,  109 and 10  s 
CD34 + cells, assuming that all CD34 + cells could be recov- 
ered from the cultures and logistics of large scale cultures 
were established. These numbers are comparable to the number 
of CD34 + cells in a typical allogeneic bone marrow graft 
(1-2  x  1010 total  nucleated  cells,  of which  1-2%  are 
CD34 +  , for a total of '-2  x  10  s CD34 + cells/allograft)  and 
are also comparable to the calculated number of CD34 + cells 
that could possibly be obtained by culture of peripheral blood 
CD34 § cells (11). Based on these numbers, further studies 
of the hematolymphoid function of the CD34 + cells pro- 
duced in cultures (i.e., in the SCID-hu mouse [31]) in rela- 
tion to different cytokine combinations seem justified. The 
rapid turnover of fetal and cord blood CD34 + cells in cul- 
ture is likely to facilitate retroviral-mediated gene transfer (32), 
and this could represent another feature favoring the use of 
such cells. Taken together, it appears that hematopoietic cells 
derived from fetal tissue or umbilical cord blood may have 
significant advantages over hematopoietic cells derived from 
adults for the development of novel gene therapy and trans- 
plantation protocols for patients with a variety of currently 
fatal disorders.  The extensive functional differences between 
primitive hematopoietic cells purified from tissues at various 
stages of development that are reported here should be con- 
sidered  in the planning of such clinical  strategies. 
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